(Q30422899)

21 June 2017

title

Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania (English)

1 reference

21 June 2017

0 references

1 reference

1 reference

Christopher B Fox

1

1 reference

21 June 2017

Chuong Huynh

series ordinal

2

1 reference

21 June 2017

Michael K O'Hara

series ordinal

3

1 reference

21 June 2017

Adrian Onu

series ordinal

4

1 reference

21 June 2017

language of work or name

English

0 references

publication date

25 October 2012

1 reference

21 June 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

21 June 2017

volume

31

1 reference

21 June 2017

issue

12

1 reference

21 June 2017

page(s)

1633-1640

1 reference

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

Squalene emulsions for parenteral vaccine and drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

7 January 2021

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.048

10.1016/J.VACCINE.2012.10.048

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference